Evidence map›Paper›PMID 28263288›Full record

Trial reportBone marrow transplantation2017

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.

Y Natori, A Humar, J Lipton, D D Kim, P Ashton, K Hoschler, D Kumar

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07485855 (Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07485855 phase3recruitingnot on this mapstarted 2025, after this paper: background citation

Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies

TypeinterventionalSponsorAsan Medical CenterRan2025 to 2028Enrolled60ConditionsHematologic Neoplasms, Influenza, ImmunogenicityArmsHigh-dose trivalent inactivated influenza vaccine (HD-IIV3), MF59-adjuvanted quadrivalent inactivated influenza vaccine (aIIV4), Standard-dose trivalent inactivated influenza vaccine (SD-IIV3)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Vaccination of Adults With Cancer: ASCO Guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  2. Pooled it
  3. Pooled it
  4. Influenza vaccines in immunosuppressed adults with cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Comparison of Two High-Dose Versus Two Standard-Dose Influenza Vaccines in Adult Allogeneic Hematopoietic Cell Transplant Recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The epidemiology of community-acquired respiratory viruses during the SARS-CoV-2 pandemic.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  17. Article
  18. Review
  19. Review
  20. Seasonal influenza vaccine in immunocompromised persons.Human vaccines & immunotherapeutics · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Y NatoriDivision of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
A HumarDivision of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
J LiptonAllogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
D D KimAllogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
P AshtonDivision of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
K HoschlerPublic Health England, London, UK.
D KumarDivision of Infectious Diseases, University Health Network, University of Toronto, Toronto, ON, Canada.
University Health Network · CAUniversity of Toronto · CAPrincess Margaret Cancer Centre · CAPublic Health England · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The annual influenza vaccine is recommended for hematopoietic stem cell transplant (HSCT) patients although studies have shown suboptimal immunogenicity. Influenza vaccine containing an oil-in-water emulsion adjuvant (MF59) may lead to greater immunogenicity in HSCT recipients. We randomized adult allogeneic HSCT patients to receive the 2015-2016 influenza vaccine with or without MF59 adjuvant. Preimmunization and 4-week post-immunization sera underwent strain-specific hemagglutination inhibition assay. We randomized 73 patients and 67 (35 adjuvanted; 32 non-adjuvanted) had paired samples available at follow-up. Median age was 54 years (range 22-74) and time from transplant was 380 days (range 85-8107). Concurrent graft-versus-host disease was seen in 42/73 (57.5%). Geometric mean titers increased significantly after vaccination in both groups. Seroconversion to at least one of three influenza antigens was present in 62.9% vs 53.1% in adjuvanted vs non-adjuvanted vaccine (P=0.42). Factors associated with lower seroconversion rates were use of calcineurin inhibitors (P<0.001) and shorter duration from transplantation (P=0.001). Seroconversion rates were greater in patients who got previous year influenza vaccination (82.6% vs 45.5%, P=0.03). Adjuvanted vaccine demonstrated similar immunogenicity to non-adjuvanted vaccine in the HSCT population and may be an option for some patients.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultAgedAntigens, ViralFemaleHumansInfluenza VaccinesMaleMiddle AgedPilot ProjectsPolysorbatesSqualeneAntigens, ViralInfluenza VaccinesMF59 oil emulsionPolysorbatesSqualene

Identifiers

PMID28263288
OpenAlexW2592253045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.